Pharmaron Beijing Co Ltd Informations sur les dividendes
Pharmaron Beijing Co Ltd a un dividende annuel de 0.3054 par action, avec un rendement de 0.00%. Le dividende est payé annuellement et la dernière date d'ex-dividende était le Jul 4, 2025.
Rendement en dividend
Dividende annuel
Date ex-dividende
0.00%
$0.3054
Jul 4, 2025
Fréquence des paiements
Taux de distribution
Annuellement
0.00%
Historique des dividendes
Date ex-dividende
Montant en espèces
Date de registre
Date de paiement
Jul 4, 2025
$0.2188
Jul 7, 2025
Aug 6, 2025
Jun 27, 2024
$0.2199
Jun 28, 2024
Jul 26, 2024
Jul 18, 2023
$0.2191
Jul 19, 2023
Aug 18, 2023
Jun 6, 2022
$0.2348
Jun 7, 2022
Jul 12, 2022
Graphiques des dividendes
PHBBF Dividendes
PHBBF Croissance des dividendes (variation annuelle)
Follow-Up Questions
Quel est le dividende actuel payé par Pharmaron Beijing Co Ltd et son dividende annuel ?
Quel est le ratio de distribution de dividendes de Pharmaron Beijing Co Ltd ?
Quelle est la date ex-dividende pour PHBBF ?
À quelle fréquence Pharmaron Beijing Co Ltd verse-t-elle des dividendes ?
Statistiques clés
Clôture préc.
$1.93
Prix d'ouverture
$1.93
Plage de la journée
$1.93 - $1.93
Plage de 52 semaines
$1.93 - $1.93
Volume
100
Volume moyen
0
BPA (TTM)
0.12
Rendement en dividend
--
Capitalisation boursière
$581.9M
Qu’est-ce que PHBBF ?
Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 21,370 full-time employees. The company went IPO on 2019-01-28. Pharmaron Beijing Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The firm operates through five segments. The Laboratory Services segment includes laboratory chemistry and bioscience services, covering small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates, and cell and gene therapy products. The Chemical and Formulation Process Development and Manufacturing Services segment includes active pharmaceutical ingredient process development and manufacturing, as well as preformulation and formulation development. The Clinical Research Services segment includes international and domestic clinical research services. The Large Molecule and Cell and Gene Therapy Services segment includes large molecule drug discovery, development, and manufacturing services, as well as cell and gene therapy laboratory and gene therapy drug development and manufacturing services. The firm also operates through the others segment.